Cargando…
Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
BACKGROUND: The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced in human malignancies due to increased ligand production, receptor overexpression, receptor mutations, and/or cross-talk with other receptor systems. For this reason, the EGFR is an attractive target fo...
Autores principales: | Fernández Lorente, Aymara, Acosta Brooks, Soraida, Neninger Vinageras, Elia, Barroso Alvarez, María del Carmen, Wilkinson Brito, Barbara, Troche Concepción, Mayelin, Martínez Pérez, Liana B, Viada González, Carmen E, Crespo Diaz, Tatiana, Casacó Parada, Angel Raymundo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853575/ https://www.ncbi.nlm.nih.gov/pubmed/24127898 http://dx.doi.org/10.1186/1477-7819-11-275 |
Ejemplares similares
-
Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
por: Popa, Xitlally, et al.
Publicado: (2020) -
Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023) -
Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
por: Lorenzo-Luaces, Patricia, et al.
Publicado: (2020) -
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
por: Evans, Rachel, et al.
Publicado: (2022) -
CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients
por: Saavedra, Danay, et al.
Publicado: (2017)